Navigation Links
Argos Therapeutics Presents Data Showing Memory T Cell Expansion After Administration of Fully Personalized Immunotherapy Correlates with Overall Survival Benefit in Patients with Metastatic Renal Cell Carcinoma
Date:11/11/2013

DURHAM, N.C., Nov. 11, 2013 /PRNewswire/ -- Argos Therapeutics Inc., a biopharmaceutical company focused on the development and commercialization of fully personalized immunotherapies for the treatment of cancer and infectious diseases using its Arcelis™ technology platform, presented an analysis of data from its Phase 2 clinical trial showing that treatment with AGS-003, the company's lead product candidate, in combination with sunitinib, induced memory T cell responses in metastatic renal cell cancer (mRCC) patients that correlated with statistical significance to overall survival (OS).  The poster, entitled "Multi-Functional Cytotoxic T Cell Expansion Correlates with Overall Survival after Administration of Autologus Dendritic Cell Immunotherapy in Renal Cell Cancer Patients," was presented on November 9 at the 28th Annual Meeting of the Society for Immunotherapy of Cancer in National Harbor, Maryland.

AGS-003, an investigational fully personalized immunotherapy, is designed to elicit an immune response by inducing CD8+CD28+ memory T cells that are known to correlate with improved clinical outcomes. In the Phase 2 trial, the Company monitored the immune responses in 14 evaluable intermediate and poor risk mRCC patients using multi-color flow cytometry. The data were analyzed for correlations between immune responses and survival using an adaptation of the bioinformatics pattern recognition algorithm, Binary Tree-Structured Vector Quantization (BTSVQ). Patients in the trial received treatment in standard six-week cycles of sunitinib plus AGS-003 every three weeks for five doses and then every 12 weeks until progression.  BTSVQ identified unique cytotoxic T cell (CTL) signatures displaying broad markers of immune function (MIFs) that were statistically significant predictors of survival duration as well as mono-functional late-stage effector T cells that inversely correlated with patient survival. 

"We believe that these additional findings from our Phase 2 trial support the in vivo mechanism of action of AGS-003," said Charles Nicolette, Argos' chief scientific officer and vice president of research and development, adding, "we also believe this is the first demonstration in a clinical trial that the magnitude of an adaptive immune response following immunotherapy correlates with prolonged survival."  

The Phase 2 clinical trial of AGS-003 in combination with sunitinib enrolled 21 intermediate and poor risk mRCC patients who had a time from diagnosis to initiation of systemic therapeutic treatment of less than one year. Fourteen of these patients were evaluable for immune responses, and median overall survival for these 14 patients was 39.5 months.

Earlier this year, Argos initiated a pivotal Phase 3 clinical trial for AGS-003 ("ADAPT"). The randomized, multicenter, open-label ADAPT clinical trial is designed to examine the potential for AGS-003 plus standard targeted drug therapy to extend OS versus standard therapy alone in newly diagnosed mRCC patients. Argos is using BTSVQ to analyze multi-color flow cytometry data in the ADAPT trial, which will enroll a total of 450 patients in approximately 130 global sites. 

About the Arcelis™ Technology Platform
Arcelis is a fully personalized immunotherapy technology that captures mutated and variant antigens that are specific to each patient's disease. It is designed to overcome immunosuppression by producing a durable memory T cell response without adjuvants that may be associated with toxicity. The technology is potentially applicable to a wide range of different cancers and infectious diseases and is designed to overcome many of the manufacturing and commercialization challenges that have impeded other personalized immunotherapies.

The Arcelis process uses only a small tumor or blood sample and the patient's own dendritic cells, which are collected and optimized following a single leukapheresis procedure. The proprietary process uses RNA isolated from the patient's disease sample to program dendritic cells to target disease antigens. The activated, antigen-loaded dendritic cells are then formulated into the patient's plasma and administered via intradermal injection.

About Argos Therapeutics
Argos Therapeutics is a biopharmaceutical company focused on the development and commercialization of fully personalized immunotherapies for the treatment of cancer and infectious diseases using its Arcelis™ technology platform.  Argos´ most advanced product candidate, AGS-003, has initiated a pivotal Phase 3 study for the treatment of mRCC, and the Company recently completed enrollment of its Phase 2b study of AGS-004 for the treatment of HIV. For more information about Argos Therapeutics, visit www.argostherapeutics.com.


'/>"/>
SOURCE Argos Therapeutics Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Argos Therapeutic Arcelis™ Immunotherapy AGS-003 in Combination With Sunitinib Shows Statistically Significant Correlation of Immune System Response to Overall Survival in Phase 2 Study in Patients with Advanced Renal Cell Carcinoma (RCC)
2. Global Aptamers Market Technology Trend Analysis Market Report 2013-2018: Therapeutics, Diagnostics, Biosensors, Biomarker/Drug Discovery & Applications
3. Acquisitions, Project Announcements & Trend Analysis News for Oxygen Biotherapeutics, Glu Mobile, Cisco Systems, Barrick Gold, CVS Caremark
4. Convoy Therapeutics Appoints Clinical Advisory Board
5. Aratana Therapeutics Inc. to Report Third Quarter 2013 Financial Results
6. United Therapeutics Corporation Reports Third Quarter 2013 Financial Results
7. The Zacks Analyst Blog Highlights: Eaton, Baxter International, Bio-Rad Laboratories, INSYS Therapeutics and Boston Scientific
8. Moderna Therapeutics Named to the World Economic Forums Community of "Global Growth Companies"
9. United Therapeutics Corporation to Announce Third Quarter 2013 Financial Results Before Market Open on Tuesday, October 29, 2013
10. PTC Therapeutics Expands Management Team
11. Relmada Therapeutics Inc. Completes $8.0 Million Capital Raise In Series A Financing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/20/2017)... -- Stock-Callers.com explores the Biotech industry to ... recent performances of select equities. In this morning,s lineup ... Abeona Therapeutics Inc. (NASDAQ: ABEO ), Theravance ... Therapeutics Inc. (NASDAQ: SAGE ). According to ... market size is expected to reach $604.40 billion by 2020 due to ...
(Date:1/20/2017)... 2017 http://www.Financialbuzz.com - ... leading causes of death worldwide. There were 8.2 million ... cancer related deaths increased gradually over time, the death ... of various cancers continues to drive demand of biological ... Global Market Insights, Inc. cancer biological therapy market size was ...
(Date:1/19/2017)... Jan 19, 2017 Research and Markets has ... Technology, Biomolecules, Cancer Type, Application - Global Opportunity Analysis and Industry ... ... the global market is projected to reach $15,737 million by 2022 ... 2016 to 2022. Omic technologies segment accounted for ...
(Date:1/19/2017)... Ky. and HOUSTON ... Inc. ("NX Prenatal") today announced the formation of ... together leading clinicians and industry veterans who enhance ... company as it accelerates development of its novel ... to provide medical, clinical and strategic guidance for ...
Breaking Biology Technology:
(Date:1/13/2017)... WASHINGTON, N.Y. , Jan. 13, 2017 /PRNewswire/ ... of technology solutions for the homecare industry, including ... of homecare industry expert, Justin Jugs, as Senior ... brings more than 15 years of homecare experience ... team in developing strategic plans to align Sandata,s ...
(Date:1/12/2017)... 12, 2017  New research undertaken by Fit Small ... future.  1,000 participants were simply asked which office technology had ... may consider standard issue.  Insights on what will ... gathered from futurists and industry leaders including Penelope Trunk ... .  Some of these findings ...
(Date:1/11/2017)... , Jan. 11, 2017 Intoxalock, a ... with the release of its patent-pending calibration device. With ... reliably perform calibrations, securely upload data logs and process ... the customer. "Fighting drunk driving through the ... the public at large, but also for the customer ...
Breaking Biology News(10 mins):